fda compounding semaglutide crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Moves to Permanently Close

Important considerations: GLP-1 receptor agonists should not replace established antihypertensive medications and should only be initiated for their licensed indications according to NICE guidance

Only about 1 in 4 required a video visit with a clinician, and 6% required a clinician call, though all 49 required the patient to fill out a questionnaire

They have gained traction in the past decade and have become mainstream in the last few years

Does Retatrutide work better for fatty liver than Mounjaro

L-Glutathione is a naturally occurring antioxidant found throughout the human body, including in the liver, spleen, and heart